Oral BCL-2 inhibitor (BH3 mimetic) that triggers mitochondrial apoptosis.
Selective oral BCL-2 inhibitor (BH3 mimetic) that binds the BCL-2 hydrophobic groove to block its anti-apoptotic function, restoring intrinsic (mitochondrial) apoptosis via MOMP and caspase activation; spares BCL-XL.
YES
DIRECT
Venetoclax directly inhibits BCL-2, releasing pro-apoptotic effectors (BAX/BAK) to cause mitochondrial outer membrane permeabilization, cytochrome c release, caspase activation, and apoptosis of BCL-2-dependent cells.
A tumor-targeted superantigen fusion protein (anti-5T4 Fab linked to a bacterial superantigen) that binds 5T4 on tumor cells and polyclonally activates T cells via TCR Vβ engagement at the tumor site.
A tumor‑targeted superantigen fusion protein in which an anti‑5T4 Fab directs the molecule to 5T4‑expressing tumor cells while the staphylococcal enterotoxin E (SEA/E‑120) moiety binds T‑cell receptors (TCR Vβ) and MHC class II, driving potent, polyclonal T‑cell activation at the tumor site and T‑cell–mediated killing of 5T4+ cancer cells.
YES
DIRECT
The anti-5T4 Fab targets 5T4+ cells and presents a superantigen (SEA/E-120) that engages TCR Vβ (with MHC II), polyclonally activating T cells to kill 5T4-expressing tumor cells via cytotoxic T-cell mechanisms.
A tumor-targeted superantigen fusion protein (anti-5T4 Fab linked to a bacterial superantigen) that binds 5T4 on tumor cells and polyclonally activates T cells via TCR Vβ engagement at the tumor site.
A tumor‑targeted superantigen fusion protein in which an anti‑5T4 Fab directs the molecule to 5T4‑expressing tumor cells while the staphylococcal enterotoxin E (SEA/E‑120) moiety binds T‑cell receptors (TCR Vβ) and MHC class II, driving potent, polyclonal T‑cell activation at the tumor site and T‑cell–mediated killing of 5T4+ cancer cells.
NO
INDIRECT
The SEA/E superantigen binds TCR Vβ on T cells and MHC II to polyclonally activate T cells, which then kill 5T4-expressing tumor cells (perforin/granzyme). TCR Vβ+ cells are engaged/activated, not directly killed.
A tumor-targeted superantigen fusion protein (anti-5T4 Fab linked to a bacterial superantigen) that binds 5T4 on tumor cells and polyclonally activates T cells via TCR Vβ engagement at the tumor site.
A tumor‑targeted superantigen fusion protein in which an anti‑5T4 Fab directs the molecule to 5T4‑expressing tumor cells while the staphylococcal enterotoxin E (SEA/E‑120) moiety binds T‑cell receptors (TCR Vβ) and MHC class II, driving potent, polyclonal T‑cell activation at the tumor site and T‑cell–mediated killing of 5T4+ cancer cells.
NO
INDIRECT
The superantigen moiety binds MHC class II to help activate T cells (via TCR Vβ), but the activated T cells are directed to kill 5T4-positive tumor cells bound by the anti-5T4 Fab; MHC II–expressing cells are not the intended cytotoxic targets.
A type II anti-CD20 glycoengineered monoclonal antibody used to deplete B cells and reduce anti-drug antibodies/modify the immune milieu.
Type II anti-CD20 glycoengineered humanized IgG1 that binds CD20 on B cells with enhanced FcγRIII affinity, driving potent ADCC/ADCP and direct, caspase‑independent cell death to deplete CD20+ B cells and modulate the immune milieu.
YES
DIRECT
Obinutuzumab binds CD20 on B cells and, via enhanced FcγRIIIa engagement, triggers NK cell–mediated ADCC and macrophage ADCP; it also induces direct, caspase‑independent cell death of CD20+ cells (with limited CDC).